|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2000-10-27
|
|
pubmed:abstractText |
The major mechanism of resistance to alkylnitrosourea therapy involves the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT), which removes chloroethylation or methylation damage from the O(6) position of guanine. O(6)-benzylguanine (O(6)-BG) is an AGT substrate that inhibits AGT by suicide inactivation. We conducted a phase I trial of carmustine (BCNU) plus O(6)-BG to define the toxicity and maximum-tolerated dose (MTD) of BCNU in conjunction with the preadministration of O(6)-BG with recurrent or progressive malignant glioma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AshleyD MDM,
pubmed-author:BignerD DDD,
pubmed-author:CokgorII,
pubmed-author:ColvinO MOM,
pubmed-author:DolanM EME,
pubmed-author:EwesuedoR BRB,
pubmed-author:FriedmanA HAH,
pubmed-author:FriedmanH SHS,
pubmed-author:Garcia-TurnerA MAM,
pubmed-author:HaglundM MMM,
pubmed-author:HerndonJ EJE2nd,
pubmed-author:LonaFF,
pubmed-author:McLendonR ERE,
pubmed-author:MoschelR CRC,
pubmed-author:PeggA EAE,
pubmed-author:PludaJJ,
pubmed-author:ProvenzaleJ MJM,
pubmed-author:QuinnJ AJA,
pubmed-author:RiceJ SJS,
pubmed-author:SampsonJJ,
pubmed-author:StewartE SES,
pubmed-author:Tourt-UhligSS
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3522-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11032594-Adult,
pubmed-meshheading:11032594-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11032594-Astrocytoma,
pubmed-meshheading:11032594-Carmustine,
pubmed-meshheading:11032594-Central Nervous System Neoplasms,
pubmed-meshheading:11032594-Drug Administration Schedule,
pubmed-meshheading:11032594-Glioblastoma,
pubmed-meshheading:11032594-Guanine,
pubmed-meshheading:11032594-Humans,
pubmed-meshheading:11032594-Middle Aged,
pubmed-meshheading:11032594-Neoplasm Recurrence, Local
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
|
|
pubmed:affiliation |
Departments of Surgery, Medicine, Pathology, Radiology, and Community and Family Medicine, Duke University Medical Center, Durham, NC 27710, USA. fried003@nc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
